Ubrogepant

🧮 Dose calculator

Acute migraine attack · Regimen source: FDA Ubrelvy · 2.1

• • Treating more than 8 migraines in 30 days not studied. Severe hepatic or renal impairment: 50 mg. FDA Ubrelvy · 2.1FDA Ubrelvy · 2.2

Enter age (weight is optional for this regimen).

👥 Special populations

• 🤰 PregnancyUse with caution

  Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Ubrelvy · 8.1

  “Risk Summary There are no adequate data on the developmental risk associated with the use of UBRELVY in pregnant women.”

• 🤱 BreastfeedingUse with caution

  Label: use with caution while breastfeeding; see the label text. FDA Ubrelvy · 8.2

  “Risk Summary Data from a lactation study in twelve healthy adult females indicate that ubrogepant is excreted in breast milk in low amounts.”

• 👶 ChildrenSafety not established

  Label: safety and effectiveness in children have not been established. FDA Ubrelvy · 8.4

  “Safety and effectiveness in pediatric patients have not been established.”

• 👴 Older adultsUse with caution

  Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Ubrelvy · 8.5

  “In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range.”

• ⚥ Females & males of reproductive potentialNo data

  The source for this drug has no section for this group.